Vasomedical

Vasomedical is engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP® ) therapy systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system diseases that is cleared by the FDA and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance, and a staff training and maintenance programs designed to provide optimal patient outcomes. The Company also provides other non-invasive medical equipment including a full range of Biox™ ECG Holter monitors recorders and ambulatory blood pressure monitors.
Company Growth (employees)
Type
Public
HQ
Plainview, US
Founded
1994
Size (employees)
218 (est)
Vasomedical was founded in 1994 and is headquartered in Plainview, US

Vasomedical Office Locations

Vasomedical has offices in Plainview and New York
Plainview, US (HQ)
200 137 Commercial St
New York, US
1702 111 John St

Vasomedical Data and Metrics

Vasomedical Financial Metrics

Vasomedical's revenue was reported to be $57.1 m in FY, 2015 which is a 63% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2015)

57.1 m

Revenue growth (FY, 2014 - FY, 2015), %

63%

Gross profit (FY, 2015)

35.4 m

Gross profit margin (FY, 2015), %

62%

Net income (FY, 2015)

3.8 m

EBIT (FY, 2015)

3.9 m

Market capitalization (24-May-2017)

14.7 m

Closing share price (24-May-2017)

0.1

Cash (31-Dec-2015)

2.2 m

EV

22.3 m
Vasomedical's current market capitalization is $14.7 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Revenue

32.9 m35 m57.1 m

Revenue growth, %

6%63%

Cost of goods sold

10.4 m9.8 m21.7 m

Gross profit

22.5 m25.2 m35.4 m

Gross profit Margin, %

68%72%62%

Operating expense total

23.8 m24.1 m31.4 m

EBIT

(1.3 m)1.1 m3.9 m

EBIT margin, %

(4%)3%7%

Interest income

87 k207 k312 k

Pre tax profit

(1.2 m)1.3 m3.8 m

Income tax expense

58 k(127 k)44 k

Net Income

(1.1 m)1.1 m3.8 m
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Cash

8 m9.1 m2.2 m

Accounts Receivable

Inventories

363 k512 k

Current Assets

25.9 m29 m18.8 m

Goodwill

3.3 m3.3 m17.5 m

Total Assets

33.5 m41 m50.4 m

Accounts Payable

597 k462 k4 m

Total Debt

326 k9.8 m

Current Liabilities

19.2 m19.8 m22.5 m

Non-Current Liabilities

7.8 m13.5 m16.2 m

Total Liabilities

27.1 m33.2 m38.7 m

Additional Paid-in Capital

61.5 m61.9 m62.3 m

Retained Earnings

(53.6 m)(52.4 m)(48.6 m)

Total Equity

6.5 m7.8 m11.7 m

Debt to Equity Ratio

0 x0.8 x

Debt to Assets Ratio

0 x0.2 x

Financial Leverage

5.2 x5.3 x4.3 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Net Income

(1.1 m)1.1 m3.8 m

Depreciation and Amortization

361 k467 k1.5 m

Accounts Receivable

Inventories

Accounts Payable

255 k(135 k)347 k

Cash From Operating Activities

(1.5 m)2.6 m6.5 m

Cash From Investing Activities

(228 k)(1.4 m)(18.3 m)

Cash From Financing Activities

(1.8 m)(46 k)4.7 m

Interest Paid

1 k196 k

Income Taxes Paid

69 k48 k130 k
Numbers are in $, USDY, 2015

EV/EBIT

5.7 x

EV/CFO

3.4 x

Revenue/Employee

261.8 k

Debt/Equity

0.8 x

Debt/Assets

0.2 x

Financial Leverage

4.3 x

Vasomedical Operating Metrics

FY, 2016

Patents (US)

11

Patents (foreign)

13

Conveyancing Completions

8

Trademarks Foreign

10

Vasomedical Market Value History

Vasomedical Online and Social Media Presence

Vasomedical Company Life and Culture

You may also be interested in